Editorial Standards

Our Editorial Process

Content published on VoltaPeptides.com is written by the Volta Peptides editorial team and carries the team byline. Where the subject falls inside his scope it also carries a named technical review by Marcus Hopkin, PhD, Director of Research and Development, shown separately from the byline with its own date. We do not attach a person's name to work they did not do. Every piece goes through a structured workflow before publication:

1. Research & Drafting: The editorial team drafts the content from primary scientific literature, registry records and regulatory documents, following our source selection standards.
2. Accuracy Review: Factual claims are checked against the cited sources, and the model, trial phase and strength of evidence behind each claim are confirmed to be stated in the text.
3. Technical Review: Content covering peptide chemistry, analytical testing, purity, identity or stability is checked for scientific and analytical accuracy by our Director of Research and Development. This is internal review by an employee. It is not peer review, independent third-party review or medical review, and no page on this site may describe it as any of those.
4. Publication & Monitoring: Published content is monitored and re-reviewed, and material errors are handled under our corrections policy.

Sourcing & Fact-Checking

We base our content on peer-reviewed research papers, regulatory filings (FDA, EMA, TGA), and verified industry sources. All factual claims are traced back to their original source.

• Primary sources include PubMed-indexed journals, clinical trial registries, and official regulatory documents.
• Claims drawn from secondary sources are independently verified against the underlying data before publication.
• Where consensus is evolving or data is preliminary, we state this explicitly and avoid presenting findings as conclusive.
• Product-related content references batch-specific Certificates of Analysis and third-party HPLC testing data.

Compliance Standards

The rules below are applied in editorial review before publication. They are constraints on what content may say, not preferences:

• No medical claims: we do not claim that any product treats, cures, prevents, or diagnoses any disease or condition.
• No dosing recommendations: we do not provide instructions for human or animal administration.
• No implied therapeutic use: content avoids language that could suggest products are intended for human consumption.
• Regulatory language is reviewed against FDA, FTC, and international advertising standards.

Content Updates

Articles and guides are regularly reviewed and updated as new research is published or regulatory landscapes change. Each article displays its original publication date and the date it was last updated, so readers always know how current the information is. When a substantive change is made, the article is re-reviewed through our full editorial process.

Corrections Policy

Our full corrections policy sets out what gets a silent edit, what gets a dated correction notice, what gets withdrawn, and the corrections we have already published.

If you identify an error in any of our published content, whether a factual inaccuracy, a broken citation, or misleading language, please contact us at team@voltapeptides.com. We will investigate promptly and, where warranted, issue a correction with a note explaining what was changed and why.

Who reviews the science

Marcus Hopkin, PhD

Director of Research and Development, Volta Peptides

Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.

Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.

Our published standards

• Source selectionWhat counts as a source here, and what does not
• CorrectionsHow errors are reported, fixed and disclosed
• Testing methodologyHow compounds are tested and what the figures mean
• ContributorsThe named people who write and review content